NVCR · NovoCure Limited

This compensation amendment reflects a strategic expansion of Dr. Weinberg’s leadership responsibilities at NovoCure, consolidating medical and innovation leadership under one executive. His dual role as both Chief Medical Officer and Chief Innovation Officer signals heightened integration of clinical development and technology advancement—core to NovoCure’s tumor treating fields platform. The stipend is narrowly scoped: it is not a base salary increase, does not affect equity grants or long-term incentives, and is explicitly excluded from AIP calculations, indicating the company intends to preserve performance-based compensation integrity while recognizing added operational scope. The arrangement is tied directly to the duration of the Chief Medical Officer assignment, suggesting potential reversibility if the role structure changes. As no other executives are referenced and no broader organizational restructuring is disclosed, the impact is contained to one named executive officer and carries no immediate financial statement implications beyond modest incremental personnel expense.